413 related articles for article (PubMed ID: 33280983)
1. The role of sodium glucose co-transporter inhibitors in heart failure prevention.
Garla V; Subauste A; Butler J; Lien LF
J Diabetes Complications; 2021 Mar; 35(3):107811. PubMed ID: 33280983
[TBL] [Abstract][Full Text] [Related]
2. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
[TBL] [Abstract][Full Text] [Related]
3. Use of sodium-glucose co-transporter-2 inhibitors in patients with and without type 2 diabetes: implications for incident and prevalent heart failure.
Butler J; Handelsman Y; Bakris G; Verma S
Eur J Heart Fail; 2020 Apr; 22(4):604-617. PubMed ID: 31926059
[TBL] [Abstract][Full Text] [Related]
4. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
[TBL] [Abstract][Full Text] [Related]
5. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
[TBL] [Abstract][Full Text] [Related]
6. Effects of sodium glucose cotransporter type 2 inhibitors on heart failure.
Nassif ME; Kosiborod M
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():19-23. PubMed ID: 31081589
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose co-transporter 2 inhibitors and heart failure-the present and the future.
Nana M; Morgan H; Bondugulapati LNR
Heart Fail Rev; 2021 Jul; 26(4):953-960. PubMed ID: 32020487
[TBL] [Abstract][Full Text] [Related]
8. Type 2 diabetes and risk of heart failure: a systematic review and meta-analysis from cardiovascular outcome trials.
Giugliano D; Maiorino MI; Longo M; Bellastella G; Chiodini P; Esposito K
Endocrine; 2019 Jul; 65(1):15-24. PubMed ID: 31028667
[TBL] [Abstract][Full Text] [Related]
9. Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.
Imran H; Nester W; Elgendy IY; Saad M
Ann Med; 2020 Aug; 52(5):178-190. PubMed ID: 32393068
[TBL] [Abstract][Full Text] [Related]
10. Potential roles of sodium-glucose co-transporter 2 inhibitors in attenuating cardiac arrhythmias in diabetes and heart failure.
Attachaipanich T; Chattipakorn SC; Chattipakorn N
J Cell Physiol; 2022 May; 237(5):2404-2419. PubMed ID: 35324001
[TBL] [Abstract][Full Text] [Related]
11. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
12. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis.
Li CX; Liang S; Gao L; Liu H
PLoS One; 2021; 16(2):e0244689. PubMed ID: 33606705
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2 Inhibitors in Heart Failure: Guide for Prescribing and Future Perspectives.
Garla VV; Butler J; Lien LF
Curr Cardiol Rep; 2021 May; 23(6):59. PubMed ID: 33961133
[TBL] [Abstract][Full Text] [Related]
15. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
16. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin for Patients with Heart Failure and Type 2 Diabetes Mellitus: Clinical Evidence in Comparison with Other Sodium-Glucose Co-transporter-2 Inhibitors and Potential Mechanism.
Liang B; Li R; Zhang P; Gu N
J Cardiovasc Transl Res; 2023 Apr; 16(2):327-340. PubMed ID: 35969357
[TBL] [Abstract][Full Text] [Related]
18. The Effects of DPP-4 Inhibitors, GLP-1RAs, and SGLT-2/1 Inhibitors on Heart Failure Outcomes in Diabetic Patients With and Without Heart Failure History: Insights From CVOTs and Drug Mechanism.
Pan X; Xu S; Li J; Tong N
Front Endocrinol (Lausanne); 2020; 11():599355. PubMed ID: 33335511
[TBL] [Abstract][Full Text] [Related]
19. Cardio-Protective Effects of Sodium-Glucose Co-Transporter 2 Inhibitors: Focus on Heart Failure.
Karangelis D; Mazer CD; Stakos D; Tzifa A; Loggos S; Verma S; Mitropoulos F
Curr Pharm Des; 2021; 27(8):1051-1060. PubMed ID: 33143620
[TBL] [Abstract][Full Text] [Related]
20. The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure.
Stachteas P; Nasoufidou A; Patoulias D; Karakasis P; Karagiannidis E; Mourtzos MA; Samaras A; Apostolidou X; Fragakis N
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
